Dr Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore. Prior to joining Immunocore in January 2019, she was President of MedImmune, AstraZeneca’s global biologics research and development unit. She was also Executive Vice President of AstraZeneca and a member of its senior executive team.
Dr Jallal serves on the Board of Elevance, Inc. and is a member of the Board of Trustees of Johns Hopkins University.
Bahija has authored more than 70 peer-reviewed publications and has more than 15 patents. She is also the immediate past president of the Association of Women in Science. Bahija was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association.
Prior to joining MedImmune, Bahija was Vice President, Drug Assessment and Development, at Chiron Corporation, where she successfully established the company’s translational medicine group. Prior to Chiron, she was part of the research team at Sugen, Inc.
Bahija received her PhD in Physiology from Université de Paris VI, France and conducted her post-doctorate work in molecular biology and oncology at the Max Planck Institute for Biochemistry in Germany.
What is Bahija Jallal's net worth?
The estimated net worth of Bahija Jallal is at least $411.52 thousand as of February 18th, 2026. Jallal owns 12,343 shares of Immunocore stock worth more than $411,516 as of March 11th. This net worth approximation does not reflect any other investments that Jallal may own. Additionally, Jallal receives an annual salary of $1,380,000.00 as CEO at Immunocore. Learn More about Bahija Jallal's net worth.
How old is Bahija Jallal?
What is Bahija Jallal's salary?
How do I contact Bahija Jallal?
Has Bahija Jallal been buying or selling shares of Immunocore?
During the past quarter, Bahija Jallal has sold $371,183.90 in shares of Immunocore stock. Most recently, Bahija Jallal sold 11,474 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a transaction totalling $371,183.90. Following the completion of the sale, the chief executive officer now directly owns 12,343 shares of the company's stock, valued at $399,296.05. Learn More on Bahija Jallal's trading history.
Who are Immunocore's active insiders?
Are insiders buying or selling shares of Immunocore?
During the last twelve months, Immunocore insiders bought shares 1 times. They purchased a total of 807,338 shares worth more than $23,994,085.36. During the last twelve months, insiders at the sold shares 6 times. They sold a total of 41,869 shares worth more than $1,429,800.39. The most recent insider tranaction occured on February, 18th when CEO Bahija Jallal sold 11,474 shares worth more than $371,183.90. Insiders at Immunocore own 10.4% of the company.
Learn More about insider trades at Immunocore. Information on this page was last updated on 2/18/2026.
